Adma Biologics (ADMA) 9.35 $ADMA Global Plasma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adma Biologics (ADMA) 9.35 $ADMA

Global Plasma Therapeutics Market 2015-2019
M2 - Wed Sep 09, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/skzsk3/global_plasma) has announced the addition of the "Global Plasma Therapeutics Market 2015-2019" report to their offering. The global plasma therapeutics market to grow at a CAGR of 12.10% over the period 2014-2019. The report covers the present scenario and the growth prospects of the global plasma therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI. The report, Global Plasma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global plasma therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Patient assistance programs for plasma therapeutics are boosting the growth of the market. Vendors nowadays provide co-pay assistance to individuals who purchase plasma therapeutics. According to the report, IVIG is the largest segment of the plasma therapeutics market. IVIG is being increasingly used due to increases in the number of bleeding disorders, CIDP, and the global aging population. This has led to increased demand for IVIG therapeutics. Further, the report states that the high cost of plasma therapeutics hinders market growth. Plasma protein therapies cost nearly four times more than other pharmaceutical medicines because of the use of expensive technologies in the manufacturing and processing of plasma-derived products. Key vendors - Baxter - CSL Behring - Grifols Therapeutics - Octapharma Other prominent vendors - Abeona Therapeutics - ADMA Biologics - Amag Pharmaceuticals - Antares Pharma - BioDelivery Sciences - Bio Products Laboratory - Biota Pharmaceuticals - Biotest Pharmaceuticals - China Biologic Products - Depomed - Emergent BioSolutions - Ethicon - Flamel Technologies - Kamada - Kedrion - King Pharmaceuticals - Nektar Therapeutics - OMRIX Biopharmaceuticals - ProMetic Life Sciences - Rockwell Medical - The Medicines - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/sk...bal_plasma
CBPO: 99.84 (+1.16), EBS: 32.58 (+0.39), ADMA: 9.35 (+0.36), BOTA: 2.08 (-0.08), ATRS: 1.91 (+0.06), NKTR: 12.24 (+0.79), ABEO: 5.48 (+0.17)

ADMA Biologics wins US patent for RI-002 immune globulin (IG)
M2 - Tue Sep 01, 5:15AM CDT
Biopharmaceutical company ADMA Biologics (NasdaqCM:ADMA) revealed on Monday that it has received the US Patent and Trademark Office's (USPTO) patent titled, 'Compositions And Methods For The Treatment of Immunodeficiency' for RI-002 immune globulin (IG) in treating immune compromised PIDD patients.
ADMA: 9.35 (+0.36)

Respiratory Syncytial Virus (RSV) Infections: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fswgvd/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects Companies Mentioned - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Celltrion, Inc. - Codagenix, Inc. - Crucell N.V. - CureVac GmbH - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Humabs BioMed SA - iBio, Inc. - Immunovaccine, Inc. - Johnson & Johnson - Kineta, Inc. - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - Microbiotix, Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation For more information visit http://www.researchandmarkets.com/research/fs...espiratory
ADMA: 9.35 (+0.36), EBS: 32.58 (+0.39), BOTA: 2.08 (-0.08), GSK: 40.26 (+0.02), JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), IBIO: 0.70 (-0.01)

Adma Biologics reports 2Q loss
Automated Insights - Tue Aug 11, 3:57PM CDT
RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Tuesday reported a loss of $4.7 million in its second quarter.
ADMA: 9.35 (+0.36)

ADMA Biologics Reports Second Quarter 2015 Results
GlobeNewswire - Tue Aug 11, 3:38PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the second quarter ended June 30, 2015, in addition to providing a corporate update and anticipated milestones for 2015.
ADMA: 9.35 (+0.36)

ADMA Biologics submits RI-002's BLA to US FDA for treating patients with PI.
M2 - Mon Aug 03, 4:44AM CDT
Biopharmaceutical company ADMA Biologics (NasdaqCM:ADMA) disclosed on Friday that it has submitted its Biologics License Application (BLA) seeking marketing authorisation for its lead product candidate RI-002 for the treatment of patients with PI. from the US Food and Drug Administration (FDA).
ADMA: 9.35 (+0.36)

ADMA Biologics Announces Submission of RI-002 Biologics License Application (BLA) to FDA
GlobeNewswire - Fri Jul 31, 8:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment and prevention of certain infectious diseases, announced that it has submitted its Biologics License Application (BLA) to the United States Food and Drug Administration (FDA), seeking marketing authorization for RI-002.
ADMA: 9.35 (+0.36)

ADMA Biologics Announces Recent Commercialization Focused Appointments
GlobeNewswire - Mon Jul 06, 6:38AM CDT
Senior Vice President of Commercialization & Strategy
ADMA: 9.35 (+0.36)

ADMA Biologics Shares Possibly Worth A Triple On FDA Approval Of RI-002
Jason Napodano, CFA - at Seeking Alpha - Tue Jun 30, 9:18AM CDT

ADMA: 9.35 (+0.36)

ADMA Biologics Receives Notice of Allowance for U.S. Patent Pertaining to Its Lead Product Candidate RI-002
GlobeNewswire - Tue Jun 30, 6:08AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application 14/592,721 entitled Compositions and Methods For The Treatment of Immunodeficiency.
ADMA: 9.35 (+0.36)

ADMA Biologics Joins Russell Microcap(R) Index
GlobeNewswire - Mon Jun 29, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment and prevention of certain infectious diseases, announced that it was added to the Russell Microcap(R) Index. The newly reconstituted indexes took effect following market close on June 26, 2015.
ADMA: 9.35 (+0.36)

ADMA Biologics to Present at the 2015 JMP Securities Life Sciences Conference
GlobeNewswire - Tue Jun 16, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2015 JMP Securities Life Sciences Conference on June 24, 2015 in New York City at The St. Regis New York.
ADMA: 9.35 (+0.36)

ADMA Biologics & Jeffrey Modell Foundation Initiate Strategic Patient Advocacy Alliance
GlobeNewswire - Thu Jun 11, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it has initiated a collaboration with the Jeffrey Modell Foundation (JMF), a global nonprofit organization dedicated to patients with Primary Immunodeficiencies (PI). There are more than 250 genetic defects that are classified under the PI umbrella. The National Institutes of Health (NIH) estimates that at least 500,000 Americans are affected, many of whom are undiagnosed. JMF programs focus on early diagnosis and meaningful treatments through research, physician and patient education, public awareness, government advocacy, patient support and newborn screening.
ADMA: 9.35 (+0.36)

Primary Immune Deficiency (PID) - Pipeline Review, H1 2015
M2 - Fri Jun 05, 10:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2rdj4/primary_immune) has announced the addition of the "Primary Immune Deficiency (PID) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - ADMA Biologics - Genethon - GlaxoSmithKline - Green Cross - Octapharma - ProMetic Life Sciences - Sangamo BioSciences - Sanofi For more information visit http://www.researchandmarkets.com/research/g2...ary_immune
ADMA: 9.35 (+0.36), SGMO: 7.96 (unch), GSK: 40.26 (+0.02)

ADMA Biologics to Present at the 2015 Marcum MicroCap Conference
GlobeNewswire - Fri May 22, 4:17PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2015 Marcum MicroCap Conference on May 28, 2015 in New York City at the Grand Hyatt New York.
ADMA: 9.35 (+0.36)

Earnings Update: Complementary Research on Tantech Holdings, Sypris Solutions, Swisher Hygiene, XTL Biopharmaceuticals, ADMA Biologics
PR Newswire - Mon May 18, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SYPR: 1.37 (+0.18), TANH: 25.35 (-2.36), ADMA: 9.35 (+0.36), SWSH: 1.19 (+0.07), XTLB: 1.83 (-0.02)

ADMA Biologics beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue May 12, 4:26PM CDT

ADMA: 9.35 (+0.36)

ADMA Biologics Reports First Quarter 2015 Results
GlobeNewswire - Tue May 12, 3:44PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the first quarter ended March 31, 2015, in addition to providing a corporate update and anticipated milestones for 2015.
ADMA: 9.35 (+0.36)

Monoclonal Antibodies Partnering Deals, Terms and Agreements 2010-2015
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m7zvsb/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering. The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors. This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in monoclonal antibody dealmaking Chapter 3 - Leading monoclonal antibody deals Chapter 4 - Big pharma monoclonal antibody deals Chapter 5 - Big biotech monoclonal antibodies deals Chapter 6 - Monoclonal antibody contracts dealmaking directory Chapter 7 - Monoclonal antibody deals by individual technology type Chapter 8 - Monoclonal antibody partnering resource center Companies Mentioned - Partial List - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shionogi - Takeda - Teva - Alexion Pharmaceuticals - Elan - Emergent BioSolutions - Galapagos - Genmab - LFB Group - Morphosys - Novo Nordisk - PDL BioPharma - Regeneron Pharmaceuticals - Seattle Genetics - Spectrum Pharmaceuticals - Swedish Orphan Biovitrum - ADMA Biologics - Alexion Pharmaceuticals - Amgen - AstraZeneca - Avecia Biologics - AVEO Pharmaceuticals - Biotest - Boehringer Ingelheim For more information visit http://www.researchandmarkets.com/research/m7zvsb/monoclonal
NVO: 56.95 (+0.37), EBS: 32.58 (+0.39), ADMA: 9.35 (+0.36), AVEO: 1.36 (unch), ALXN: 171.93 (+0.28), AMGN: 153.21 (+0.07), SPPI: 6.71 (+0.17), REGN: 533.30 (+2.08), PDLI: 5.34 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 71

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 595

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 49

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 103

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 15

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 18

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading

Top 5 Most Recently Viewed Articles

Groundbreaking Grant for Vision Restoration Research at CU

Updated Category News Views 174

Innovative Funding to Restore Vision The University of Colorado Anschutz Medical Campus has secured a significant opportunity—up to $46 million from a federal agency aimed at pioneering research in health. This funding, coming from the Advanced Research Projects Agency for Health (ARPA-H), is intended to propel efforts towards achieving successful whole eye...

Continue Reading
Transocean's Strategic Acquisition: A New Era in Offshore Drilling

Updated Category News Views 279

Transocean Takes a Bold Step in Offshore Drilling Transocean Ltd. has made a definitive move to solidify its leadership position in the offshore drilling landscape. By announcing its acquisition of Valaris Limited in an all-stock deal valued at approximately $5.8 billion, Transocean is not just expanding its operations; it is setting a new benchmark in the energy services...

Continue Reading
Rexford Industrial Realty Sees 5.4% Growth in Q3 2023

Updated Category News Views 64

Rexford Industrial Realty Achieves Impressive Q3 Performance Rexford Industrial Realty, Inc. (NYSE: REXR) reported an impressive 5.4% increase in funds from operations (FFO) per share for the third quarter of 2023, reaching a total of $0.59. This substantial growth demonstrates the company’s ability to navigate the ever-changing market landscape effectively. Alongside...

Continue Reading
Tilray Brands Poised to Share Financial Insights Soon

Updated Category News Views 206

Tilray Brands Preparing for Upcoming Financial Announcement Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a transformative leader in the lifestyle and consumer packaged goods sectors, is set to reveal its financial results for the third quarter of fiscal 2025. This significant update will cover the quarter ending February 28, 2025, and...

Continue Reading
Lam Research Corporation Elevates Dividend to New Heights

Updated Category News Views 98

Lam Research Corporation Elevates Dividend to New Heights Recently, Lam Research Corporation (NASDAQ: LRCX) made a noteworthy announcement regarding its quarterly dividend payments. The company’s Board of Directors approved a 13% increase, raising the dividend from $0.23 to $0.26 per share. This decision underscores the company's commitment to rewarding its shareholders...

Continue Reading